BiomX, a microbiome company developing both natural and engineered phage therapies, announced yesterday that it has named Merav Bassan, PhD, as its new chief development officer.

In the new role, Dr Bassan will manage the company's pre-clinical and clinical development as the company advances its phage therapies into the clinic.

Dr Bassan was most recently vice president head of Translational Sciences at Teva Pharmaceutical Industries Inc. Prior to this role, Dr Bassan served as vice president of Project Leadership at Teva Pharmaceutical, where she managed project leaders overseeing end-to-end drug development at pre-clinical, PI-III and post marketing stages in multiple therapeutic areas, such as pain, oncology, women's health, endocrinology, GI, biosimilars and other areas. In total, Dr Bassan has more than 20 years of leadership experience with clinical and drug development teams in her various roles at Teva Pharmaceutical and other smaller biotech companies. Dr Bassan is also a member of the Israeli 8400 health network, a cross-sector network of leaders actualising the global disruptive capabilities of Israel's HealthTech ecosystem.